Mohamad-Ali Salloum is a Pharmacist and science writer. He loves simplifying science to the general public and healthcare students through words and illustrations. When he's not working, you can usually find him in the gym, reading a book, or learning a new skill.
Clinical Trials Phases Timeline
Mohamad-Ali Salloum, PharmD • October 18, 2025
Share
🧬 Clinical Trial Phases Timeline
From laboratory to market: The journey of drug development and testing
3-6 years
Preclinical Research
Laboratory & Animal Testing
Initial laboratory and animal studies to test safety and biological activity.
Purpose: Test the drug's safety and biological activity in laboratory settings before human testing begins.
3-6
Years Duration
1000s
Compounds Tested
~5
Advance to Trials
Key Activities:
- In vitro (test tube) studies on cells and tissues
- Animal testing for toxicity and dosing
- Pharmacokinetics (how the body processes the drug)
- Manufacturing process development
Real Example: COVID-19 mRNA Vaccines
Pfizer-BioNTech and Moderna spent months in 2020 testing their mRNA vaccine candidates in laboratory cell cultures and animal models (mice, ferrets, and non-human primates) to demonstrate safety and immune response before moving to human trials.
Several months
Phase I Clinical Trial
First-in-Human Studies
Small group testing for safety, dosage, and side effects in humans.
Purpose: Determine the drug's safety profile, identify side effects, and find the optimal dosage range in humans.
20-100
Participants
70%
Success Rate
6-12
Months Duration
Key Focus Areas:
- Maximum tolerated dose (MTD)
- Dose-limiting toxicities (DLTs)
- Pharmacokinetics and metabolism
- Initial efficacy signals
Participants: Usually healthy volunteers or patients with advanced disease who have exhausted other treatment options.
Real Example: Keytruda (Pembrolizumab)
Merck's cancer immunotherapy drug Keytruda began Phase I trials in 2009 with 30 patients with advanced solid tumors. The study tested escalating doses to find the maximum safe dose and observed promising anti-tumor activity, leading to accelerated development.
Several months to 2 years
Phase II Clinical Trial
Efficacy Testing
Larger group testing to evaluate effectiveness while monitoring safety.
Purpose: Evaluate the drug's effectiveness for specific conditions while continuing to monitor safety in a larger patient population.
100-300
Participants
33%
Success Rate
6-24
Months Duration
Study Types:
- Phase IIa: Pilot efficacy studies (100-200 participants)
- Phase IIb: Well-controlled efficacy studies (200-300 participants)
- Often randomized and may include placebo controls
- Multiple dosing regimens may be tested
Key Outcomes: Response rates, progression-free survival, quality of life measures, and biomarker analysis.
Real Example: Humira (Adalimumab)
AbbVie's Humira underwent Phase II trials for rheumatoid arthritis in the late 1990s with 284 patients. The study demonstrated significant improvement in joint symptoms compared to placebo, with 53% of patients achieving a 20% improvement in symptoms versus 19% on placebo.
1-3 years
Phase III Clinical Trial
Large-Scale Confirmation
Large-scale studies comparing the new treatment to current standard treatments.
Purpose: Confirm the drug's effectiveness, compare it to existing treatments, and collect comprehensive safety data needed for regulatory approval.
1,000-3,000
Participants
25-30%
Success Rate
1-3
Years Duration
Study Characteristics:
- Randomized, controlled, often double-blind
- Multiple study sites (often international)
- Comparison to standard of care or placebo
- Rigorous statistical analysis plans
- Independent data monitoring committees
Regulatory Importance: These studies provide the primary evidence for FDA approval applications (NDAs/BLAs).
Real Example: Lipitor (Atorvastatin)
Pfizer's Lipitor completed multiple Phase III trials including the landmark ASCOT-LLA study with 10,305 patients. The trial showed a 36% reduction in heart attacks compared to placebo, leading to its approval and eventual status as the world's best-selling drug.
Ongoing after approval
Phase IV Post-Market Surveillance
Real-World Monitoring
Ongoing monitoring of long-term effects and rare side effects in the general population.
Purpose: Monitor long-term safety and effectiveness in real-world conditions, identify rare adverse events, and study drug interactions.
10,000+
Participants
Ongoing
Duration
Required
By FDA
Study Types:
- Pharmacovigilance: Spontaneous adverse event reporting
- Registry studies: Long-term patient databases
- Comparative effectiveness research: Real-world comparisons
- Risk evaluation studies: Specific safety concerns
Regulatory Actions: Can lead to label updates, dosing changes, new warnings, or in rare cases, market withdrawal.
Real Example: Vioxx (Rofecoxib) Withdrawal
Merck's arthritis drug Vioxx was withdrawn in 2004 after Phase IV studies revealed increased cardiovascular risks. The APPROVE study, designed to show cancer prevention benefits, instead showed a doubled risk of heart attacks after 18 months of use, leading to voluntary market withdrawal.
Positive Example: Gardasil HPV Vaccine
Merck's HPV vaccine has been monitored through Phase IV surveillance since 2006. Real-world data from countries with high vaccination rates shows dramatic reductions in cervical precancers and genital warts, confirming the vaccine's effectiveness beyond clinical trials.
Preclinical Research
Phase I - Safety
Phase II - Efficacy
Phase III - Confirmation
Phase IV - Surveillance
References
- U.S. Food and Drug Administration. Clinical Trials Guidance Documents [Internet]. Silver Spring (MD): FDA; [cited 2025 Oct 18]. Available from: https://www.fda.gov/science-research/clinical-trials-and-human-subject-protection/clinical-trials-guidance-documents
- European Medicines Agency. ICH E8 (R1) General considerations for clinical trials [Internet]. Amsterdam: EMA; [cited 2025 Oct 18]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e-8-general-considerations-clinical-trials-step-5_en.pdf
- European Medicines Agency. Clinical Trials Regulation (EU No 536/2014) [Internet]. Amsterdam: EMA; [cited 2025 Oct 18]. Available from: https://www.ema.europa.eu/en/human-regulatory-overview/research-development/clinical-trials-human-medicines/clinical-trials-regulation
- International Council for Harmonisation. ICH E8 (R1) General considerations for clinical studies – Draft guideline [Internet]. Geneva: ICH; [cited 2025 Oct 18]. Available from: https://database.ich.org/sites/default/files/E8-R1_EWG_Draft_Guideline.pdf
List of Services
ABOUT THE AUTHOR
Mohamad-Ali Salloum, PharmD
Share
Recent articles:
How modern psychotherapy, neurosciencebased interventions, and personalized medicine are reshaping addiction treatment
How substance use progresses from experimentation to compulsive addiction.
How emotional dysregulation, traumatic experiences, and chronic stress shape vulnerability to addiction.
References: Biological Psychiatry Study. HDAC5 limits expression of Scn4b and regulates drug memory formation and relapse. ScienceDaily. 2025. 1 Fang Y, Sun Y, Liu Y, et al. Neurobiological mechanisms and clinical treatment of addiction. Psychoradiology. 2022;2(4):180189. 2 Palombo P. Neurobiology of Substance Use Disorders. Springer; 2025. 3 
How scientific models explain the roots and progression of addictive behavior
References: Karimpourvazifehkhorani A, Hekmati I. Habit loop in addictive behaviors formation among adolescents: The mediating role of impulsivity. Curr Psychol. 2025;44:4313–4325. Simón Márquez MM, Fernández Gea S, Molero Jurado MM, et al. Addictions and risk behaviors in adolescence: A systematic review. Front Psychol. 2025;16. Legends Recovery. The Science Behind Habit Formation and Breaking Addictive Patterns. 2025. Buabang EK, Donegan KR, Rafei P, Gillan CM. Leveraging cognitive neuroscience for making and breaking real-world habits. Trends Cogn Sci. 2025;29(1):41–59. Aguilar-Yamuza B, Trenados Y, Herruzo C, et al. A systematic review of treatment for impulsivity and compulsivity. Front Psychiatry. 2024;15. Science News Today. Why Habits Stick: The Hidden Psychology of Habit Formation. 2025.
References: Peng Z, Jia Q, Mao J, et al. Neurotransmitters crosstalk and regulation in the reward circuit of subjects with behavioral addiction . Front Psychiatry. 2024;15. 2 Walid R. The Impact of Addiction on the Brain’s Reward Circuitry, And How This Affects the Motivation and Decision-Making Processes . 2025. 3 Parra-Abarca J, Palacios-Pérez HB, Baldivia-Noyola P, et al. The relation between the dopaminergic system, drug addiction, and brain structures related to reward behaviors and decision-making . Rev Mex Neurocienc. 2025. 4 Penn LPS Online. Neuroscience and addiction: Unraveling the brain's reward system . 2025. 1 Cold Spring Harbor Laboratory. Hijacking the Brain’s Reward System: The Neuroscience Behind Addiction . 2025.
References: Aggarwal D, Naik J, Lindquist DH. Biphasic Model of Addiction: Neurobehavioral Adaptations . Curr Behav Neurosci Rep. 2025;12:25. 1 Blithikioti C, Fried EI, Albanese E, Field M, Cristea IA. Reevaluating the brain disease model of addiction . Lancet Psychiatry. 2025;12(6):469–474. 2 Blithikioti C, Fried EI, Albanese E, Field M, Cristea IA. Reevaluating the BrainDisease Model of Addiction (Accepted Version). University of Sheffield; 2025. Unterrainer HF. Addiction, attachment, and the brain: a focused review of empirical findings and future directions . Front Hum Neurosci. 2025;19. 3 Vaswani M. Neurobiology of Addiction . Addiction Behavioral Conference 2025. Magnus Group. 
This guide breaks down why your body reacts the way it does, how misinterpretation fuels anxiety, and the CBT tools designed to help you understand (and stop fearing) your own physical sensations.